Gallbladder Cancer (MSK, 2022)

Summary

Gallbladder Cancer (MSK, 2022) is a study catalogued by cBioPortal DataHub under the cancer-type code gbc. EvidenceHelix groups it with liver, bile duct and gallbladder studies.

Study description

Targeted sequencing of 244 Gallbladder cases via MSK-IMPACT where investigators calculated the Overall survival time for 100 metastatic gallbladder patients.

Text as published in the source's study metadata.

Citation & PubMed

Nicolas A et al. Clin Cancer Res 2022

Linked PubMed records: PMID 36228155

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

gbc_mskcc_2022

Short name

not given

Source cancer-type code

gbc

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Nicolas A et al. Clin Cancer Res 2022

• PubMed record 36228155 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Gallbladder Cancer (MSK, Cancer 2018)

  Targeted Sequencing of 103 samples with matched normals from 101 Gallbladder cancer patients.

  Liver, bile duct and gallbladderMSK studiesSource code gbcPubMed 1

• Gallbladder Carcinoma (Shanghai, Nat Genet 2014)

  Whole exome sequencing of 32 gallbladder carcinoma tumor/normal pairs.

  Liver, bile duct and gallbladderOther published and consortium studiesSource code gbcPubMed 1

• Cholangiocarcinoma (MSK, Clin Cancer Res 2018)

  Targeted sequencing (MSK-IMPACT) of 195 tumor samples (194 with matched normals) from 192 cholangiocarcinoma patients.

  Liver, bile duct and gallbladderMSK studiesSource code cholPubMed 1

• Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)

  MSK-IMPACT sequencing of 127 Hepatocellular Carcinoma tumor samples with matched normals.

  Liver, bile duct and gallbladderMSK studiesSource code hccPubMed 1

• Hepatocellular Carcinoma (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 1,370 hepatobiliary cancer samples (with 1366 matched normals) via MSK-IMPACT. This data is available under the Creative Commons BY-NC-ND 4.0 license (https://creativecommons.org/licenses/by-nc-…

  Liver, bile duct and gallbladderMSK studiesSource code hccPubMed 1

• Hepatocellular Carcinoma (MSK, JCO Precis Oncol 2023)

  Targeted sequencing of 51 hepatocellular carcinoma patients and their matched normal samples via MSK-IMPACT.

  Liver, bile duct and gallbladderMSK studiesSource code hccPubMed 1

• Intrahepatic Cholangiocarcinoma (MSK, Clin Cancer Res 2021)

  Targeted sequencing of IMPACT and CMO samples

  Liver, bile duct and gallbladderMSK studiesSource code ihchPubMed 1

• Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)

  Targeted sequencing of 412 intrahepatic cholangiocarcinoma tumor/normal sample pairs.

  Liver, bile duct and gallbladderMSK studiesSource code ihchPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.